Table 2

Biological pathways associated with SSKB genes
Rank PATHWAY SSKB Genes ENRICHMENT Raw P Adjust P
1 Allograft rejection 23 76.02 3.62E-39 6.82E-38
2 Intestinal immune network for IgA production 27 67.82 7.26E-44 2.05E-42
3 Asthma 14 58.61 4.14E-22 2.75E-21
4 Type I diabetes mellitus 20 57.09 9.13E-31 9.38E-30
5 Graft-versus-host disease 18 53.83 3.21E-27 2.79E-26
6 Autoimmune thyroid disease 22 52.13 1.29E-32 1.82E-31
7 Primary immunodeficiency 14 50.24 6.38E-21 3.79E-20
8 Hematopoietic cell lineage 33 47.1 1.39E-46 5.24E-45
9 Toll-like receptor signaling pathway 37 46.01 1.13E-51 6.38E-50
10 Apoptosis 25 35.68 5.55E-32 6.97E-31
11 NOD-like receptor signaling pathway 17 34.44 7.61E-22 4.78E-21
12 Amyotrophic lateral sclerosis (ALS) 14 33.18 5.81E-18 2.85E-17
13 Other glycan degradation 4 31.4 6.67E-06 1.24E-05
14 Cytokine-cytokine receptor interaction 66 31.05 5.91E-79 6.68E-77
15 T cell receptor signaling pathway 26 30.24 4.12E-31 4.66E-30
16 RIG-I-like receptor signaling pathway 17 30.07 9.98E-21 5.64E-20
17 Cell adhesion molecules (CAMs) 32 29.99 6.40E-38 1.03E-36
18 Bladder cancer 10 29.9 1.06E-12 3.24E-12
19 Viral myocarditis 17 29.25 1.68E-20 9.04E-20
20 Cytosolic DNA-sensing pathway 13 29.16 5.78E-16 2.42E-15
21 Pancreatic cancer 15 26.17 1.88E-17 8.50E-17
22 Small cell lung cancer 16 23.92 7.32E-18 3.45E-17
23 Glycosaminoglycan degradation 4 23.92 2.13E-05 3.65E-05
24 Natural killer cell mediated cytotoxicity 25 22.92 1.06E-26 8.56E-26
25 ErbB signaling pathway 13 22.16 2.51E-13 8.86E-13
26 Epithelial cell signaling in Helicobacter pylori infection 12 22.16 2.64E-13 9.04E-13
27 Complement and coagulation cascades 12 21.84 3.17E-13 1.05E-12
28 B cell receptor signaling pathway 13 21.77 3.38E-14 1.23E-13
29 Prion diseases 6 21.53 3.27E-07 6.84E-07
30 Antigen processing and presentation 15 21.17 5.49E-16 2.39E-15
31 Colorectal cancer 14 20.93 6.14E-15 2.48E-14
32 Adipocytokine signaling pathway 11 20.62 6.05E-12 1.80E-11
33 Chemokine signaling pathway 30 19.83 7.80E-30 7.35E-29
34 Prostate cancer 14 19.76 1.42E-14 5.53E-14
35 Glioma 10 19.32 1.10E-10 2.89E-10
36 Jak-STAT signaling pathway 23 18.64 1.67E-22 1.18E-21
37 Non-small cell lung cancer 8 18.61 1.13E-08 2.50E-08
38 Melanoma 10 17.69 2.71E-10 6.96E-10
39 Pathways in cancer 46 17.51 9.85E-43 2.23E-41
40 Fc epsilon RI signaling pathway 11 17.49 3.90E-11 1.05E-10
41 Chronic myeloid leukemia 10 16.75 4.74E-10 1.19E-09
42 GnRH signaling pathway 12 14.92 3.42E-11 9.43E-11
43 Leukocyte transendothelial migration 14 14.9 7.91E-13 2.48E-12
44 VEGF signaling pathway 9 14.87 1.04E-08 2.35E-08
45 Hypertrophic cardiomyopathy (HCM) 10 14.78 1.67E-09 4.10E-09
46 p53 signaling pathway 8 14.56 8.19E-08 1.75E-07
47 Endometrial cancer 6 14.49 3.65E-06 7.11E-06
48 Systemic lupus erythematosus 16 14.35 3.27E-14 1.23E-13
49 MAPK signaling pathway 30 14.01 3.15E-25 2.37E-24
50 Focal adhesion 22 13.75 1.21E-18 6.21E-18
51 Dilated cardiomyopathy 10 13.65 3.66E-09 8.44E-09
52 Type II diabetes mellitus 5 13.36 3.63E-05 6.12E-05
53 Neurotrophin signaling pathway 13 12.96 3.17E-11 8.96E-11
54 ECM-receptor interaction 8 11.96 3.85E-07 7.91E-07
55 Alzheimer's disease 16 11.89 6.32E-13 2.04E-12
56 Lysosome 11 11.81 2.86E-09 6.73E-09
57 Arginine and proline metabolism 5 11.63 7.15E-05 0.0001
58 Renal cell carcinoma 6 10.77 2.09E-05 3.63E-05
59 Long-term depression 6 10.77 2.09E-05 3.63E-05
60 Long-term potentiation 6 10.77 2.09E-05 3.63E-05
61 Proteasome 4 10.47 0.0006 0.0009
62 Progesterone-mediated oocyte maturation 7 10.22 6.00E-06 1.15E-05
63 TGF-beta signaling pathway 7 10.11 6.48E-06 1.22E-05
64 Regulation of actin cytoskeleton 16 9.3 2.69E-11 7.79E-11
65 Calcium signaling pathway 13 9.17 2.36E-09 5.67E-09
66 Wnt signaling pathway 11 9.15 4.17E-08 9.06E-08
67 Gap junction 6 8.37 8.67E-05 0.0001
68 Cell cycle 8 7.85 9.32E-06 1.70E-05
69 Oocyte meiosis 7 7.71 3.80E-05 6.31E-05
70 Axon guidance 7 6.82 8.33E-05 0.0001
71 Endocytosis 10 6.72 2.93E-06 5.81E-06
72 Metabolic pathways 26 2.96 1.12E-06 2.26E-06

The table lists the number of SSKB genes associated with individual KEGG pathways. The pathways are ranked according to their Enrichment relative to the number of reference genes in the human genome based on the hypergeometric test. The raw P-values (hypergeometric test) and the multiple test-adjusted P-values are listed for each pathway.

Gorr et al.

Gorr et al. BMC Musculoskeletal Disorders 2012 13:119   doi:10.1186/1471-2474-13-119

Open Data